About 100 reports

  • 2 Type 2 Diabetes (T2D): Executive Summary
  • 12.1 BIBLIOGRAPHY

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026 Summary Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic ?-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle (Stumvoll et al., 2010). It is well...

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • TYPE 2 DIABETES DRUGS MARKET IN APAC
  • TYPE 2 DIABETES DRUGS MARKET IN AMERICAS

About Type 2 Diabetes Diabetes, often referred to as diabetes mellitus, is a metabolic disease in which the patients' blood glucose levels remains high. Depending on the cause of development of diabetes, it can be divided into three types: - Type 1 diabetes (or insulin-dependent diabetes mellitus): In this condition, the pancreas...

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, 2016 and 2026
  • 2.1 RELATED REPORTS

Comparison of the prevalence of chronic kidney disease in Japanese patients with type ## and type ## diabetes.

  • Type 2 Diabetes
  • Germany
  • United States
  • World
  • Forecast
  • DEFRONZO RA, ET AL. (2014). NOVEL AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES. DIABETES SPECTRUM; 27: 100-112
  • VAN AMBURGH JA (2015). WHY SELECT EXTENDED-RELEASE METFORMIN? MEDSCAPE MULTISPECIALTY. AVAILABLE FROM: HTTP://WWW.MEDSCAPE.COM/VIEWARTICLE/845753 [ACCESSED ON JUNE 7, 2017]

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth Summary Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results...

  • Type 2 Diabetes
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.
  • Type 2 Diabetes Development Stages for Pipeline Drugs
  • Top Targets for Pipeline Drug Development Against Type 2 Diabetes

Type 2 Diabetes: Competitive Landscape to 2026 Summary Type 2 Diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic ?-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle.Insulin is a hormone that regulates the glucose level...

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

Global Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 2 Diabetes
  • France
  • United States
  • World
  • Forecast
  • FEATURES OF TYPE 2 DIABETES MELLITUS PATIENTS
  • Netherlands Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 2 Diabetes Mellitus in 22 Major Markets Type 2 diabetes mellitus (T2DM) is a cluster of diseases characterised by high levels of blood glucose, as well as inability of the body to produce sufficient insulin coupled with systemic desensitisation...

  • Type 2 Diabetes
  • East Asia
  • North America
  • Northern Europe
  • Scandinavia

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • United States
  • Market Shares
  • Market Size

Europe Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 2 Diabetes
  • Europe
  • France
  • Germany
  • Forecast

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • Germany
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United States
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Japan
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Germany
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United Kingdom
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • France
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Italy
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Spain
  • Market Size
  • TYPE 2 DIABETES GENE THERAPY
  • TYPE 2 DIABETES RECOMBINANT FUSION PROTEIN

“Type 2 Diabetes (T2D) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of T2D. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules,...

  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • 4.3 ETIOLOGY AND PATHOPHYSIOLOGY
  • Case Flow Map

PREVALENCE OF TYPE ## AND TYPE ## DIABETES AMONG CHILDREN AND ADOLESCENTS FROM 2001 TO 2009.

  • Type 2 Diabetes
  • Forecast
  • Daiichi Sankyo Company
  • Depomed, Inc.
  • Pfizer Inc.
  • 5.3 GLOBAL AND HISTORICAL TRENDS
  • MM, DIAGNOSED PREVALENCE OF DME IN THE DIAGNOSED DIABETIC RETINOPATHY POPULATION,

The upsurge in DME prevalence will be driven by the US and ##EU, where it is expected to increase at a CAGR of ##% directly following the increases expected for type ## and type ## diabetes.

  • Type 2 Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Drug analysis: Farxiga

9091 10000 7727

Drug analysis: Farxiga PRODUCT PROFILES Farxiga : Diabetes type ## Farxiga : Diabetes type ## LIST OF FIGURES Figure ##: Farxiga for type ## diabetes – SWOT analysis Figure ##: Datamonitor Healthcare drug assessment of Farxiga Figure ##: Datamonitor Healthcare drug assessment s

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Overview: Invokana TABLE OF CONTENTS ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Invokana for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Invokana in

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Analysis: Invokana TABLE OF CONTENTS ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Invokana for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Invokana in d

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Overview: Farxiga

9091 10000 7727

Drug Overview: Farxiga TABLE OF CONTENTS ## Product Profiles ## Farxiga : Diabetic nephropathy ## Farxiga : Diabetes type ## ## Farxiga : Chronic heart failure (CHF) ## Farxiga : Diabetes type ## LIST OF FIGURES ## Figure ##: Farxiga for diabetic nephropathy – SWOT analysis ## Figure

  • Chronic Disease
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Analysis: Jardiance TABLE OF CONTENTS & nbsp; ## Product Profiles ## Jardiance : Diabetic nephropathy ## Jardiance : Chronic heart failure (CHF) ## Jardiance : Diabetes type ## LIST OF FIGURES ## Figure ##: Jardiance for diabetic nephropathy – SWOT analysis ## Figure ##: Datamoni

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

Drug Overview: Jardiance TABLE OF CONTENTS ## Product Profiles ## Jardiance : Diabetic nephropathy ## Jardiance : Chronic heart failure (CHF) ## Jardiance : Diabetes type ## LIST OF FIGURES ## Figure ##: Jardiance for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Health

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand
  • MM, Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population, 2016
  • 3.2 RISK FACTORS AND COMORBIDITIES

sequence=##.

  • Type 2 Diabetes
  • Germany
  • Spain
  • United States
  • Forecast
  • Case Flow Map
  • 2.2 UPCOMING REPORTS

PREVALENCE OF TYPE ## AND TYPE ## DIABETES AMONG CHILDREN AND ADOLESCENTS FROM 2001 TO 2009.

  • Hospital
  • Type 2 Diabetes
  • United States
  • World
  • Forecast
  • Type 2 Diabetes Mellitus, Global, Percentage
  • Type 2 Diabetes Mellitus, Global, Ratio of First-in-

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease Summary Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of...

  • Diabetes
  • Insulin
  • Type 2 Diabetes
  • World
  • Deals & Alliance
  • 2.2 RISK FACTORS AND COMORBIDITIES
  • 2.4 FORECAST METHODOLOGY

DIABETOLOGIA; ##(##): ##-##.

  • Type 2 Diabetes
  • Japan
  • United Kingdom
  • United States
  • Forecast